相似文献
1
Unraveling the genetic susceptibility to HBV-related liver cancer: The role of virus-host immune interactions.
Hepatology. 2025 Apr 15. doi: 10.1097/HEP.0000000000001355.
2
The loss of hepatitis B virus receptor NTCP/SLC10A1 in human liver cancer cells is due to epigenetic silencing.
J Virol. 2024 Oct 22;98(10):e0118724. doi: 10.1128/jvi.01187-24. Epub 2024 Sep 19.
3
A novel chronic hepatitis B mouse model with immune activation and liver fibrosis.
Microbiol Spectr. 2025 Jul 24:e0251324. doi: 10.1128/spectrum.02513-24.
4
Identification and characterization of host factor VCPIP1 as a multi-functional positive regulator of hepatitis B virus.
J Virol. 2024 Dec 17;98(12):e0158124. doi: 10.1128/jvi.01581-24. Epub 2024 Nov 4.
5
Prevalence, Risk Factors, and Clinical Profiles of Hepatitis D Virus in Nigeria: A Systematic Review, 2009-2024.
Viruses. 2024 Oct 31;16(11):1723. doi: 10.3390/v16111723.
6
AAV-HBV mouse model replicates the intrahepatic immune landscape of chronic HBV patients at single-cell level.
Front Immunol. 2025 Jun 18;16:1421712. doi: 10.3389/fimmu.2025.1421712. eCollection 2025.
7
SLC16A3 as an immunosuppressive Kupffer cell marker predicts poor prognosis in HBV-positive hepatocellular carcinoma.
J Transl Med. 2025 Sep 2;23(1):988. doi: 10.1186/s12967-025-06861-0.
8
Comparative Risk of Hepatitis B Virus Reactivation in Patients Receiving Immune Checkpoint Inhibitors or Tyrosine Kinase Inhibitors for Liver Cancer.
Aliment Pharmacol Ther. 2025 Sep 5. doi: 10.1111/apt.70367.
9
Innate immune recognition in hepatitis B virus infection.
Virulence. 2025 Dec;16(1):2492371. doi: 10.1080/21505594.2025.2492371. Epub 2025 Apr 20.
10
Impact of artificial liver plasma perfusion combined with plasma exchange therapy on clinical efficacy and short-term prognosis of hepatitis B virus-related acute-on-chronic liver failure with or without HIV infection.
BMC Infect Dis. 2025 Aug 30;25(1):1081. doi: 10.1186/s12879-025-11496-z.
本文引用的文献
1
Behaviour-Based Predictive Scores of Hepatocellular Carcinoma in People With Chronic Hepatitis B (ANRS CO22 HEPATHER).
Liver Int. 2025 Apr;45(4):e70065. doi: 10.1111/liv.70065.
2
Prevention of liver cancer in the era of next-generation antivirals and obesity epidemic.
Hepatology. 2025 Jan 14. doi: 10.1097/HEP.0000000000001227.
3
Phase 3 Validation of PAaM for Hepatocellular Carcinoma Risk Stratification in Cirrhosis.
Gastroenterology. 2025 Mar;168(3):556-567.e7. doi: 10.1053/j.gastro.2024.10.035. Epub 2024 Nov 8.
4
Functional cure of hepatitis B in patients with cancer undergoing immune checkpoint inhibitor therapy.
J Hepatol. 2025 Jan;82(1):51-61. doi: 10.1016/j.jhep.2024.07.018. Epub 2024 Jul 29.
5
Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma.
Nat Rev Clin Oncol. 2024 Apr;21(4):294-311. doi: 10.1038/s41571-024-00868-0. Epub 2024 Feb 29.
6
HBV reactivation and clinical resolution in an isolated anti-HBc-positive patient during immune checkpoint inhibition.
Med. 2024 Feb 9;5(2):126-131.e1. doi: 10.1016/j.medj.2024.01.002.
7
Genetic variants in five novel loci including CFB and CD40 predispose to chronic hepatitis B.
Hepatology. 2015 Jul;62(1):118-28. doi: 10.1002/hep.27794. Epub 2015 Apr 28.
8
GWAS identifies novel susceptibility loci on 6p21.32 and 21q21.3 for hepatocellular carcinoma in chronic hepatitis B virus carriers.
PLoS Genet. 2012;8(7):e1002791. doi: 10.1371/journal.pgen.1002791. Epub 2012 Jul 12.
Zotero 插件